"We are pleased to collaborate with the Leukemia and Lymphoma Society which is funding a Phase 1 investigator-sponsored trial of OXi4503 in AML. We anticipate seeing some initial data from this trial in late 2012 and final data in the first half of 2013.
We believe that these data, if they are positive, will provide additional evidence of the broad clinical utility of our VDA pipeline, and attract additional commercial interest from potential partners. That is our major reason to continue to invest at a low level in maintaining these promising programs, and establishing collaborations that offset our expenses and enable them to advance without significant direct cost to the company."
"We are continuing to collaborate with the Gynecologic Oncology Group as they conduct a Phase 2 trial in relapsed ovarian cancer. Interim data from this trial could be available in the second half of 2012"